ClinicalTrials.gg
CompletedNCT06060977Updated Feb 9, 2026Results posted

A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Alopecia Areata Participants

A Phase 1/2 interventional study of IMG-007 in Alopecia Areata (AA), sponsored by Inmagene LLC. Completed at 17 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-09.

Sponsored by Inmagene LLC · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
29
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies in Alopecia Areata with a site in United States — 21 open to participants now, 32 under way, 8 of them phase 3. Alopecia Areata · United States.

Enrollment
54th of 84
29 · median 46
Started
2023
with 8 others
Phase 1/2
2 of 98
none open now
Registered
76th of 98
by date

Among the 98 studies in Alopecia Areata with a site in United States, this one is the 54th largest by enrollment of the 84 interventional ones that give a count, is one of 9 that started in 2023, is one of 2 in phase 1/2, and was the 76th registered.

Alopecia Areata

220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.

Browse Alopecia Areata studies →

Open to participants now

21 of the 98 studies in Alopecia Areata with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies in Alopecia Areata with a site in United States, or all of them as a file.
02

Study summary

The primary objective of the study is to evaluate the safety of IMG-007 in adults with Alopecia Areata.

Read the detailed description

This is a phase 1b/2a, open label study to assess the safety, PK, and efficacy of IMG-007 in adult AA participants with 50% or greater scalp hair loss. The study will consist of two cohorts with three periods: a screening period of up to 5 -weeks, a 16-week treatment period and a 20-week follow- up period. Approximately 6 and 24 participants will be sequentially enrolled into cohort 1 and cohort 2, respectively, to receive three intravenous infusions of IMG-007 over 4 weeks.

03

Conditions studied

  • Alopecia Areata (AA)

Keywords

  • IMG-007
  • Alopecia Areata
  • Alopecia
  • Hair Loss
  • Skin Disease
  • Immune System Disorder
  • Dermatologic Agents
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male or female aged ≥ 18 and ≤ 65 years
  • AA with current episode of hair loss of > 6 months but \< 8 years
  • AA with ≥ 50% scalp involvement as defined as SALT score ≥ 50

Key Exclusion Criteria:

  • Known , , or infection
  • Evidence of active or latent tuberculosis (TB)
  • History of untreated or inadequately treated TB infection.
  • Active infection requiring treatment with systemic antibiotics, antivirals, antifungals, antiparasitics or antiprotozoals at the Screening visit
  • Concurrent hair loss due to other etiologies
  • Primary "diffuse" type of AA
  • Active inflammatory diseases on the scalp that would interfere with the assessment of AA
  • History or presence of hair transplants or micropigmentation of the scalp
  • Active systemic diseases that may cause hair loss
  • Other conditions or laboratory abnormality that could increase the risk associated with study participation or could interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    IMG-007 Dose 1 (300 mg)

    IMG-007 Dose 1 (300 mg) will be administered intravenously 3 times over 4 weeks

    Drug: IMG-007

  • Experimental
    IMG-007 Dose 2 (600 mg)

    IMG-007 Dose 2 (600 mg) will be administered intravenously 3 times over 4 weeks

    Drug: IMG-007

Interventions

06

What researchers measure

Primary outcomes

  1. Evaluation of Adverse Events in Participants

    To evaluate adverse events (AEs) emergent from multiple doses of IMG-007 in adult participants with AA.

    Time frame: Adverse events were collected from baseline through the end of the study, a period of up to 24 weeks.

Secondary outcomes

  1. Evaluation of Severity of Alopecia Tool (SALT)

    To evaluate the efficacy of multiple doses of IMG-007 in AA participants as measured by the Severity of Alopecia Tool (SALT). The Severity of Alopecia Tool (SALT) is a quantitative assessment of AA severity by the investigator based on scalp terminal hair loss. To evaluate the efficacy of multiple doses of IMG-007 in AA participants as measured by Severity of Alopecia Tool (SALT) on a scale of 0 for no hair loss, and 100 is complete hair loss (higher scores attributes to worse outcomes).

    Time frame: Mean percent change from baseline in Severity of ALopecia Tool (SALT) at week 24.

07

Results

Posted Feb 9, 2026

Participant flow

Participant flow — Overall Study
MilestoneIMG-007 300 mgIMG-007 600 mg
Started623
Completed523
Not completed10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryEvaluation of Adverse Events in Participants

To evaluate adverse events (AEs) emergent from multiple doses of IMG-007 in adult participants with AA.

Time frame:
Adverse events were collected from baseline through the end of the study, a period of up to 24 weeks.
Reported as:
Count of participants · Participants
Evaluation of Adverse Events in Participants
ParticipantsIMG-007 300 mgIMG-007 600 mg
Participants with at least 1 TEAE319
SAE00
TEAE that was an infusion-related reaction10
TEAE leading to 4-week dosing period discontinuation00
TEAE with outcome of death00
SecondaryEvaluation of Severity of Alopecia Tool (SALT)

To evaluate the efficacy of multiple doses of IMG-007 in AA participants as measured by the Severity of Alopecia Tool (SALT). The Severity of Alopecia Tool (SALT) is a quantitative assessment of AA severity by the investigator based on scalp terminal hair loss. To evaluate the efficacy of multiple doses of IMG-007 in AA participants as measured by Severity of Alopecia Tool (SALT) on a scale of 0 for no hair loss, and 100 is complete hair loss (higher scores attributes to worse outcomes).

Time frame:
Mean percent change from baseline in Severity of ALopecia Tool (SALT) at week 24.
Reported as:
Least squares mean · percentage of change
Evaluation of Severity of Alopecia Tool (SALT)
percentage of changeIMG-007 300 mgIMG-007 600 mg
Evaluation of Severity of Alopecia Tool (SALT)-1.07 ± 7.593-14.32 ± 3.875

Adverse events

Collected over Adverse events were collected from baseline through the end of the study, a period of up to 24 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IMG-007 300 mg0/6 (0%)0/6 (0%)2/6 (33.3%)
IMG-007 600 mg0/23 (0%)0/23 (0%)8/23 (34.8%)
Most frequent other events
Most frequent other events
EventIMG-007 300 mgIMG-007 600 mg
HeadacheNervous system disorders2/62/23
HypertensionVascular disorders0/62/23
NasopharyngitisInfections and infestations0/62/23
Streptococcal infectionInfections and infestations0/62/23

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)IMG-007 300 mgIMG-007 600 mgTotal
<=18 years000
Between 18 and 65 years62329
>=65 years000
Age, Continuous
Age, Continuous(years)IMG-007 300 mgIMG-007 600 mgTotal
Mean42.2 ± 15.5144.7 ± 15.0544.2 ± 14.90
Sex: Female, Male
Sex: Female, Male(Participants)IMG-007 300 mgIMG-007 600 mgTotal
Female61622
Male077
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)IMG-007 300 mgIMG-007 600 mgTotal
Hispanic or Latino022
Not Hispanic or Latino62127
Unknown or Not Reported000
Severity of ALopecia Tool (SALT) Score
Severity of ALopecia Tool (SALT) Score(units on a scale)IMG-007 300 mgIMG-007 600 mgTotal
Mean87.23 ± 15.65178.63 ± 18.40180.41 ± 17.954
08

Study locations

17 sites
  • Northwest Arkansas Clinical Trials Center, PLLC/ Hull Dermatology P.A.
    Rogers, Arkansas 72758, United States
  • Torrance Clinical Research Institute Inc.
    Lomita, California 90717, United States
  • Alliance Clinical Research of Tampa
    Tampa, Florida 33615, United States
  • Dawes Fretzin Clinical Resarch Group, LLC
    Indianapolis, Indiana 47906, United States
  • Options Research Group
    West Lafayette, Indiana 47906, United States
  • Lahey Hospital & Medical Center
    Burlington, Massachusetts 01803, United States
  • Great Lakes Research Group Inc.
    Bay City, Michigan 48706, United States
  • Skin Cancer and Dermatology Institute
    Reno, Nevada 89509, United States
  • Skin Search of Rochester, Inc.
    Rochester, New York 14623, United States
  • Stride Clinical Research LLC
    Sugar Land, Texas 77479, United States
  • Dermatology Specialists of Spokane
    Spokane, Washington 99202, United States
  • SimcoMed Health Ltd.
    Barrie, Ontario L4M7G1, Canada
  • Skin Health
    Cobourg, Ontario K9A0Z4, Canada
  • Guelph Dermatology Research
    Guelph, Ontario N1L0B7, Canada
  • Research Toronto
    Toronto, Ontario M2W2N4, Canada
  • Centre de Recherche Saint-Louis
    Québec, Quebec G1W4R4, Canada
  • Innovaderm Research Inc.
    Montreal, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2023 to primary completion in Jan 2025, 15 months.

Results were first posted in Feb 2026, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2023
First posted
Sep 29, 2023
StartActual
Sep 25, 2023
Primary completionActual
Jan 14, 2025
CompletionActual
Jan 14, 2025
Results first posted
Feb 9, 2026
Last update
Feb 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06060977
Lead sponsor
Inmagene LLC
Responsible party
Sponsor
First posted
Sep 29, 2023
Start date
Sep 25, 2023
Primary completion
Jan 14, 2025
Completion
Jan 14, 2025
Results posted
Feb 9, 2026
Last update
Feb 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IMG-007

Start the discussion